NCT01810913 2026-03-13
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
National Cancer Institute (NCI)
University of Erlangen-Nürnberg Medical School
Bicara Therapeutics
BioNTech SE
NRG Oncology
Inhibrx Biosciences, Inc
Privo Technologies
Shanghai Jiao Tong University School of Medicine